With considerable resources being devoted to KOLs in this new era of heightened public visibility and scrutiny, it is critical that pharmaceutical, biotech and medical device companies restrict payments only to their Medical Affairs and Marketing KOLs ...
The post KOL Payments in the Time of Scrutiny appeared first on Knowledge Hub Media.